NNC0519-0130 Effect on Oral Contraceptives and Gastric Emptying

Phase 1, open-label, single-arm trial of NNC0519-0130 in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady state at Day 188 and Area under the levonorgestrel plasma concentration time curve during a dosing interval at steady state at Day 188. Started Jul 2024; status: completed.